Senhwa Biosciences, Inc.

NT$29.05As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6492Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (16.04%)
Div yield —
ROE (39.03%)
Biotechnology
Beta (5Y) 0.71
PE TTM —
TSR TTM (35.10%)
Mkt cap NT$2.597B
ROIC (24.47%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$30
4.27%
(23.16%)
Hold 12|11|1|10|8
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.30
0.33
0.33
0.32
4.16%
9.58%
4.74%
5.81%
RevenueNT$M
242.1
249.8
246.2
255.8
18.25%
15.87%
8.12%
6.03%
Peers (US$78.43M)
Cap (US$)
PE
78.36M
—
Capital
TTM
5Y
10Y
Leveragex
0.877
(0.048)
(0.051)
EBIT/Intx
0.657
0.323
0.260
Own earn%
(61.01)
4.31
3.59
Sh yield%
53.65
55.42
48.54
Owners
Insiders/Inst%
6.30
60.71
Short interest%
3.71
SBC / revenue%
4.96
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
5–15
$1 testx
0.2
Incr. ROIC%
17